Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits

References

• Terry TL. Fibroblastic overgrowth of persistent tunica vasculosa lentis in infants born prematurely: II. Report of cases – clinical aspects. Trans Am Ophthalmol Soc 1942;40:262–284.
   Google Scholar
• Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol 2009;148(3):451–458.
   PubMed Web of Science ®Google Scholar
• Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005;115(5):e518–e525.
   PubMed Web of Science ®Google Scholar
• Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024–1028.
   PubMed Web of Science ®Google Scholar
• Robinson GS, Ju M, Shih SC, et al. Nonvascular role for VEGF: VEGFR-1, -2 activity is critical for neural retinal development. FASEB J 2001;15:1215–1217.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arring PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–1487.
   PubMed Web of Science ®Google Scholar
• Wells J, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularization. Br J Ophthalmol 1996;80:363–366.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Brown LF, Detmar M, Dvorak M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029–1039.
   PubMed Web of Science ®Google Scholar
• Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology 2009;116(11):2165–2169.
   PubMed Web of Science ®Google Scholar
• Sonmez K, Drenser KA, Capone A Jr, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008;115(6):1065–1070.
   PubMed Web of Science ®Google Scholar
• Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009;116(9):1599–1603.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364(7):603–615.
   PubMed Web of Science ®Google Scholar
• Harder BC, Baltz SV, Jonas JB, Schlichtenbrede FC. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol 2014;92:577–581.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Chen SN, Hwang JF. Intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight infant with rush type retinopathy of prematurity. Oman J Ophthalmol 2012;5(3):184–186.
   PubMedGoogle Scholar
• Chun-Ju Lin S-NC, Chien-Chi T, Yao-Chung C, Jiunn-Feng H. Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity: a preliminary report. Taiwan J Ophthalmol 2012;2(4):136–139.
   Google Scholar
• Mota A, Carneiro A, Breda J, Rosas V, Magalhaes A, Silva R, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol 2012;3(1):136–141.
   PubMedGoogle Scholar
• Wu WC, Lai CC, Chen KJ, et al. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci 2010;51:3701–3708.
   PubMed Web of Science ®Google Scholar
• Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999;19:5731–5740.
   PubMed Web of Science ®Google Scholar
• Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 2000;97:10242–10247.
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maharaj ASR, Walshe TE, et al. Endogenous VEGF Is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One 2008;3(11):e3554.
   PubMed Web of Science ®Google Scholar
• Manzano RPA, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257–261.
   PubMed Web of Science ®Google Scholar
• Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006;26:882–888.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162–164.
   PubMed Web of Science ®Google Scholar
• Inan UU, Avci B, Kusbeci T, et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48:1773–1781.
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726–733.
   PubMed Web of Science ®Google Scholar
• Guo B, Wang Y, Hui Y, Yang X, Fan Q. Effects of anti-VEGF agents on rat retinal Müller glial cells. Mol Vis 2010;16:793–799.
   PubMed Web of Science ®Google Scholar
• Peters S, Heiduschka P, Julien S. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995–1002.
   PubMed Web of Science ®Google Scholar
• Thaler S, Fiedorowicz M, Choragiewicz TJ. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage. Acta Opthalmol 2010;88:e170–e176.
   PubMed Web of Science ®Google Scholar
• Zayit-Soudry S, Zemel E, Barak A, Perlman I, Loewenstein A. Safety of intravitreal bevacizumab in the developing rabbit retina. Retina 2011;31(9):1885–1895.
   PubMed Web of Science ®Google Scholar
• Fusco MA, Portes ALF, Allodi S, Moraes HV Jr, Monteiro MLR, Miguel NCO. Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after shortterm treatment with intravitreous bevacizumab. Clinics 2012;67:1–7.
   Web of Science ®Google Scholar
• Miguel NC, Matsuda M, Portes AL. In vitro effects of bevacizumab treatment on newborn rat retinal cell proliferation, death, and differentiation. Invest Ophthalmol Vis Sci 2012;53:7904–7911.
   PubMed Web of Science ®Google Scholar
• Tokunaga CC, Mitton KP, Dailey W, et al. Effects of anti- VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2014;55:1884–1892.
   PubMed Web of Science ®Google Scholar
• Reichenbach A, Schnitzer J, Friedrich A, Ziegert W, Bruckner G, Schober W. Development of the rabbit retina. I. Size of eye and retina, and postnatal cell proliferation. Anat Embryol (Berl) 1991;183:287–297.
   PubMedGoogle Scholar
• Linden R, Rehen SK, Chiarini LB. Apoptosis in developing retinal tissue. Prog Retin Eye Res 1999;18:133–165.
   PubMed Web of Science ®Google Scholar
• Boya P, Mellen MA, de la Rosa EJ. How autophagy is related to programmed cell death during the development of the nervous system. Biochem Soc Trans 2008;36:813–817.
   PubMed Web of Science ®Google Scholar
• Miller, JW, Adamis AP, et al. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997;13:37–50.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Northrup JM, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995a;113:1538–1544.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Pierce EA, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457–10461.
   PubMed Web of Science ®Google Scholar
• Ida H, Tobe T, et al. RPE cells modulate subretinal neovascularization, but do not cause regression in mice with sustained expression of VEGF. Invest Ophthalmol Vis Sci 2003;44:5430–5437.
   PubMed Web of Science ®Google Scholar
• Robbins SG, Conaway JR, et al. Detection of vascular endothelial growth factor (VEGF) protein in vascular and non-vascular cells of the normal and oxygen-injured rat retina. Growth Factors. 1997;14:279–295.
   PubMed Web of Science ®Google Scholar
• Stone J, Itin A, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738–4747.
   PubMed Web of Science ®Google Scholar
• Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167(5):1451–1459.
   PubMed Web of Science ®Google Scholar
• Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999;155(2):421–428.
   PubMed Web of Science ®Google Scholar
• Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171(1):53–67.
   PubMed Web of Science ®Google Scholar
• Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez-Barrios P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008;126(8):1161–1163.
   PubMedGoogle Scholar
• Malik D, Tarek M, Carpio JC, Ramirez C, Boyer D, Kenney MC, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol 2014;98:11–16.
   PubMed Web of Science ®Google Scholar
• Miura Y, Klettner A, Roider J. VEGF-antagonists decrease barrier function of retinal pigment epithelium in vitro – possible participation of intracellular glutathione. Invest Ophthalmol Vis Sci 2010;51:4848–4855.
   PubMed Web of Science ®Google Scholar
• Klettner A, Mohle F, Roider J. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch Clin Exp Ophthalmol 2010;248:819–824.
   PubMed Web of Science ®Google Scholar
• Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J. Different properties of VEGF-antagonists: bevacizumab but not ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 2009;247:1601–1608.
   PubMed Web of Science ®Google Scholar
• Schnichels S, Hagemann U, Januschowski K, et al. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br J Ophthalmol 2013;97:917–923.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179–2182.
   PubMed Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327–333.
   PubMed Web of Science ®Google Scholar
• Lee S-J, Kim S-Y, Yoo B, Kim HW, Kim YH. Plasma level of vascular endothelial growth factor in retinopathy of prematurity after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci 2011;52:3165, E-abstract 3165.
   Google Scholar
• Avery RL, Castellarin A, Steinle N, et al. Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab and Aflibercept In Patients With Neovascular AMD. Br J Ophthalmol 2014;98(12):1636–1641.
   PubMed Web of Science ®Google Scholar
• Chan-Ling T, Stone J. Degeneration of astrocytes in feline retinopathy of prematurity causes failure of the blood-retinal barrier. Invest Ophthalmol Vis Sci 1992;33:2148–2159.
   PubMed Web of Science ®Google Scholar